Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road

Abstract

Get full access to this article

View all access options for this article.

References

Farrell

Espandin

Lakdawala

. Incorporation of an Interferon beta neutralising antibody assay into routine clinical practice. Mult Scler [THIS ISSUE].

Uzeé

Di Marco

Mouchel-Vielh . Domains of interaction between alphainterferon and its receptor components. J Mol Biol 1994; 243: 245–257.

Cheriyath

Leaman

Borden

. Emerging roles of FAM14 familymembers (G1P3/ISG 6–16 and ISG12/IFI27) in innate immunity and cancer. J Interferon Cytokine Res 2011; 31: 173–181.

Goodin

Frohman

Hurwitz

. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977–984.

Pachner

Polman

Deisenhammer

. Neutralizing antibodies tointerferon beta: assessment of their clinical and radiographic impact: an evidencereport: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 69: 1552–1556.

Goodin

Hurwitz

Noronha

. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007; 35: 173–187.

Farrell

Bendtzen

Bertolotto

. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2008; 36: 204–210.

Graves

. Survey Errors and Survey Costs. New York: John Wiley and Sons, 1989.

Lam

Farrell

Aziz

. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods 2008; 336: 113–118.

10.

Prentice

. Surrogate endpoints in clinical trials: Definition and operationalcriteria. Stat Med 1989; 8: 431–440.